Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus

On evaluation, she had severe painful erosions on the gingiva, palate, buccal mucosa, tongue, and posterior pharynx. Because of refractory severe disease, she received her first course of rituximab (375 mg/m2 weekly x 4) in January 2007. [...]we report the development of inhibitory IgG HACAs in a pe...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2012-09, Vol.130 (3), p.800-803
Main Authors: Lunardon, Luisa, MD, Payne, Aimee S., MD, PhD
Format: Article
Language:English
Subjects:
Adult
Allergy and Immunology
Animals
Antibodies - blood
Antibodies, Monoclonal, Murine-Derived - immunology
Autoimmune diseases
Biological and medical sciences
Bullous diseases of the skin
Dermatology
Female
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Humans
Immune system
Immunoglobulin G - blood
Immunopathology
Labeling
Medical sciences
Medical treatment
Mice
Pemphigus - drug therapy
Recombinant Fusion Proteins - immunology
Rituximab
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Software
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On evaluation, she had severe painful erosions on the gingiva, palate, buccal mucosa, tongue, and posterior pharynx. Because of refractory severe disease, she received her first course of rituximab (375 mg/m2 weekly x 4) in January 2007. [...]we report the development of inhibitory IgG HACAs in a pemphigus patient who did not achieve disease remission after rituximab therapy.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2012.03.022